WO2023089132A1 - Injectable and inhalable formulations - Google Patents
Injectable and inhalable formulations Download PDFInfo
- Publication number
- WO2023089132A1 WO2023089132A1 PCT/EP2022/082486 EP2022082486W WO2023089132A1 WO 2023089132 A1 WO2023089132 A1 WO 2023089132A1 EP 2022082486 W EP2022082486 W EP 2022082486W WO 2023089132 A1 WO2023089132 A1 WO 2023089132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- dimethyltryptamine
- compound
- salt
- optionally substituted
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 428
- 238000009472 formulation Methods 0.000 title claims abstract description 384
- -1 dimethyltryptamine compound Chemical class 0.000 claims abstract description 149
- 150000003839 salts Chemical class 0.000 claims abstract description 133
- 238000000034 method Methods 0.000 claims abstract description 76
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical class O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000012458 free base Substances 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 230000001337 psychedelic effect Effects 0.000 claims abstract description 24
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 23
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 23
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 18
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 18
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 17
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 claims description 147
- 239000000872 buffer Substances 0.000 claims description 91
- 150000001875 compounds Chemical class 0.000 claims description 87
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 71
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 66
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 64
- 239000012929 tonicity agent Substances 0.000 claims description 54
- 239000003795 chemical substances by application Substances 0.000 claims description 51
- 239000002585 base Substances 0.000 claims description 50
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 42
- 239000002253 acid Substances 0.000 claims description 40
- 239000003002 pH adjusting agent Substances 0.000 claims description 31
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 26
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 24
- 235000011054 acetic acid Nutrition 0.000 claims description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 23
- 235000015165 citric acid Nutrition 0.000 claims description 22
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 238000001671 psychotherapy Methods 0.000 claims description 18
- 239000001530 fumaric acid Substances 0.000 claims description 17
- 235000011087 fumaric acid Nutrition 0.000 claims description 17
- 229910052805 deuterium Inorganic materials 0.000 claims description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 15
- 229940088679 drug related substance Drugs 0.000 claims description 15
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 14
- 241000720974 Protium Species 0.000 claims description 14
- 159000000021 acetate salts Chemical class 0.000 claims description 14
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 13
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 13
- 208000019901 Anxiety disease Diseases 0.000 claims description 12
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 11
- 208000020401 Depressive disease Diseases 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000006184 cosolvent Substances 0.000 claims description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 8
- 239000011975 tartaric acid Substances 0.000 claims description 8
- 235000002906 tartaric acid Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 201000009032 substance abuse Diseases 0.000 claims description 7
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 claims description 6
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000174 gluconic acid Substances 0.000 claims description 6
- 235000012208 gluconic acid Nutrition 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 231100000736 substance abuse Toxicity 0.000 claims description 6
- 208000011117 substance-related disease Diseases 0.000 claims description 6
- 208000001613 Gambling Diseases 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 239000011261 inert gas Substances 0.000 claims description 5
- 206010002942 Apathy Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 239000013011 aqueous formulation Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 15
- 208000025966 Neurological disease Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 32
- 239000000126 substance Substances 0.000 description 28
- 238000003860 storage Methods 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 17
- 239000007924 injection Substances 0.000 description 17
- 238000007918 intramuscular administration Methods 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 239000007853 buffer solution Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- QVDSEJDULKLHCG-UHFFFAOYSA-N psilocybin Chemical compound C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 13
- 235000014632 disordered eating Nutrition 0.000 description 12
- 235000011007 phosphoric acid Nutrition 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 208000030814 Eating disease Diseases 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 208000024714 major depressive disease Diseases 0.000 description 11
- 208000019454 Feeding and Eating disease Diseases 0.000 description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 235000011167 hydrochloric acid Nutrition 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 206010026749 Mania Diseases 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- RTLRUOSYLFOFHV-UHFFFAOYSA-N [3-[2-(dimethylamino)ethyl]-1h-indol-4-yl] acetate Chemical compound C1=CC(OC(C)=O)=C2C(CCN(C)C)=CNC2=C1 RTLRUOSYLFOFHV-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 230000000144 pharmacologic effect Effects 0.000 description 9
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- DMULVCHRPCFFGV-WFGJKAKNSA-N 2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine Chemical compound [2H]C([2H])([2H])N(CCC1=CNC2=C1C=CC=C2)C([2H])([2H])[2H] DMULVCHRPCFFGV-WFGJKAKNSA-N 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- OHMVTPSXVQQKPA-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(1h-indol-3-yl)-n,n-dimethylethanamine Chemical group OC(=O)\C=C\C(O)=O.C1=CC=C2C(CCN(C)C)=CNC2=C1 OHMVTPSXVQQKPA-WLHGVMLRSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 208000020925 Bipolar disease Diseases 0.000 description 6
- 239000006171 Britton–Robinson buffer Substances 0.000 description 6
- 206010010219 Compulsions Diseases 0.000 description 6
- 206010029897 Obsessive thoughts Diseases 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 235000005686 eating Nutrition 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 239000001509 sodium citrate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- COCNDHOPIHDTHK-UHFFFAOYSA-N 5-methoxyindole-3-acetic acid Chemical group COC1=CC=C2NC=C(CC(O)=O)C2=C1 COCNDHOPIHDTHK-UHFFFAOYSA-N 0.000 description 5
- 206010012374 Depressed mood Diseases 0.000 description 5
- 208000011688 Generalised anxiety disease Diseases 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- ZSTKHSQDNIGFLM-WFGJKAKNSA-N 2-(5-methoxy-1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine Chemical compound [2H]C([2H])([2H])N(CCC(C1=C2)=CNC1=CC=C2OC)C([2H])([2H])[2H] ZSTKHSQDNIGFLM-WFGJKAKNSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 201000009916 Postpartum depression Diseases 0.000 description 4
- 208000014679 binge eating disease Diseases 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 230000009429 distress Effects 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 4
- 208000007656 osteochondritis dissecans Diseases 0.000 description 4
- 208000019906 panic disease Diseases 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 235000011083 sodium citrates Nutrition 0.000 description 4
- 239000001488 sodium phosphate Substances 0.000 description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 description 4
- 235000011008 sodium phosphates Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 208000029364 generalized anxiety disease Diseases 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000001117 sulphuric acid Substances 0.000 description 3
- 235000011149 sulphuric acid Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- LASOXKFMZMXTOD-UHFFFAOYSA-N 2-(4-methoxy-1h-indol-3-yl)acetic acid Chemical compound COC1=CC=CC2=C1C(CC(O)=O)=CN2 LASOXKFMZMXTOD-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- HFYHBTWTJDAYGW-UHFFFAOYSA-N 4-meo-dmt Chemical compound COC1=CC=CC2=C1C(CCN(C)C)=CN2 HFYHBTWTJDAYGW-UHFFFAOYSA-N 0.000 description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 208000010235 Food Addiction Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 206010034912 Phobia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 238000011953 bioanalysis Methods 0.000 description 2
- 208000025307 bipolar depression Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 235000008242 dietary patterns Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 239000003196 psychodysleptic agent Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DMULVCHRPCFFGV-OSEHSPPNSA-N 1,1,2,2-tetradeuterio-2-(1h-indol-3-yl)-n,n-dimethylethanamine Chemical compound C1=CC=C2C(C([2H])([2H])C([2H])(N(C)C)[2H])=CNC2=C1 DMULVCHRPCFFGV-OSEHSPPNSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- SPCIYGNTAMCTRO-QAUOGBTHSA-N 2,7-dideuterio-3-[1,1,2,2-tetradeuterio-2-(dimethylamino)ethyl]-1H-indol-4-ol Chemical compound [2H]C([2H])(C([2H])([2H])N(C)C)C1=C([2H])NC2=C1C(O)=CC=C2[2H] SPCIYGNTAMCTRO-QAUOGBTHSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000013884 Avoidant Restrictive Food Intake disease Diseases 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- RTLRUOSYLFOFHV-XERRXZQWSA-N C(C)(=O)OC1=C2C(=CNC2=CC=C1)CCN(C([2H])([2H])[2H])C([2H])([2H])[2H] Chemical compound C(C)(=O)OC1=C2C(=CNC2=CC=C1)CCN(C([2H])([2H])[2H])C([2H])([2H])[2H] RTLRUOSYLFOFHV-XERRXZQWSA-N 0.000 description 1
- DMULVCHRPCFFGV-MGVXTIMCSA-N C1=CC=C2C(CC([2H])([2H])N(C)C)=CNC2=C1 Chemical compound C1=CC=C2C(CC([2H])([2H])N(C)C)=CNC2=C1 DMULVCHRPCFFGV-MGVXTIMCSA-N 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010016374 Feelings of worthlessness Diseases 0.000 description 1
- 206010016754 Flashback Diseases 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010048533 Hypervigilance Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010027387 Merycism Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- WSDRAZIPGVLSNP-UHFFFAOYSA-N O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O Chemical group O.P(=O)(O)(O)O.O.O.P(=O)(O)(O)O WSDRAZIPGVLSNP-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000011390 Rumination Syndrome Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- DMULVCHRPCFFGV-TXNVYZHYSA-N [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C1=CNC2=CC=CC=C12 Chemical compound [2H]C([2H])([2H])N(C([2H])([2H])[2H])C([2H])([2H])C([2H])([2H])C1=CNC2=CC=CC=C12 DMULVCHRPCFFGV-TXNVYZHYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CDXSJGDDABYYJV-UHFFFAOYSA-N acetic acid;ethanol Chemical compound CCO.CC(O)=O CDXSJGDDABYYJV-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000016709 aortopulmonary window Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000005445 isotope effect Effects 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- IFYDWYVPVAMGRO-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)NCCCN(C)C IFYDWYVPVAMGRO-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000015212 rumination disease Diseases 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009517 secondary packaging Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229950004777 sodium calcium edetate Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Definitions
- the present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof.
- the aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and water, with a pH from 5 to 6.5, and a concentration of the optionally substituted dimethyltryptamine compound of about 10 mg/ml or greater as the freebase equivalent.
- the formulations may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- These formulations comprise an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less.
- Such formulations are surprisingly suitable both for intramuscular (IM) injection and nebulised inhalation, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.
- N,N-dimethyltryptamine is also understood to hold therapeutic value as a short-acting psychedelic.
- DMT N,N-dimethyltryptamine
- HMDB Human Metabolome Database
- the present invention relates to aqueous pharmaceutical formulations suitable for both intramuscular injection and nebulised inhalation, comprising about 10 mg/ml or greater (as freebase equivalent) of a salt of an optionally substituted dimethyltryptamine compound, and water, wherein the formulations have pH values of from 5 to 6.5 and typical osmolalities of from about 250 to about 350 mOsm/Kg.
- the formulations may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- formulations are capable of delivering an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy (pharmacological-assisted psychotherapy) within a volume of 5 ml or less, making them particularly suitable for both intramuscular injection and nebulised inhalation.
- the formulations are capable of delivering an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the present invention addresses the problem of providing pharmaceutical formulations suitable for intramuscular injection or nebulised inhalation with substantially reduced degradation products compared with known formulations when stored under standard or stressed conditions. This is indicative of improved shelf-life over such known pharmaceutical formulations.
- deuterated optionally substituted dimethyltryptamine compounds such as deuterated compounds of Formula IA or IB, show significantly improved exposure and Cmax by intramuscular injection, compared with their undeuterated analogues (see Figures 1 A and 1 B).
- the present invention provides for the first time an aqueous pharmaceutical formulation with an effective dose (for at least an average weight human) of an optionally substituted dimethyltryptamine compound via intramuscular injection or nebulised inhalation with a volume of 5 ml or less, preferably 4 ml or less, or 3 ml or less, or 2.5 ml or less, or 2 ml or less, or 1 ml or less, or 0.5 ml or less.
- the invention provides a pharmaceutical formulation suitable for both intramuscular injection and nebulised inhalation, comprising a salt of an optionally substituted dimethyltryptamine compound, a base agent, water; and optionally a buffer which is separate to the salt; wherein the formulation has a pH of from about 5 to about 6.5, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg.
- the formulation may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- the formulation comprises from about 10 mg/ml to about 150 mg/ml, from about 10 mg/ml to about 100 mg/ml, from about 10 mg/ml to about 80 mg/ml, from about 15 mg/ml to about 70 mg/ml, from about 15 mg/ml to about 50 mg/ml, or from about 20 mg/ml to about 40 mg/ml (as freebase equivalent) of a salt of an optionally substituted dimethyltryptamine compound.
- the formulation comprises about 25 mg/ml (as freebase equivalent) of a salt of an optionally substituted dimethyltryptamine compound.
- the pharmaceutical formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the invention provides a kit suitable for preparing a formulation of the first aspect, said kit comprising a salt of an optionally substituted dimethyltryptamine compound; a base agent, optionally a buffer which is separate to the salt, and optionally a tonicity agent and/or pH adjuster.
- the kit comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the invention provides a method of preparing a pharmaceutical formulation of the first aspect, comprising contacting the salt, water, a base agent, optionally a buffer which is separate to the salt, and optionally a tonicity agent and/or pH adjuster.
- the formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the formulation or kit of the first and second aspect comprises a tonicity agent. In some embodiments, the formulation or kit of the first and second aspect comprises a pH adjuster. In some embodiments, the formulation or kit of the first and second aspect comprises a buffer. In some embodiments, the formulation or kit of the first and second aspect comprises a buffer and a tonicity agent. In some embodiments, the formulation or kit of the first and second aspect comprises a buffer and a pH adjuster. In some embodiments, the formulation or kit of the first and second aspect comprises a buffer, a tonicity agent and a pH adjuster.
- solutions comprising optionally substituted dimethyltryptamine compounds are generally prepared immediately before or close to the time of use, i.e. storage of solutions of optionally substituted dimethyltryptamine compounds is avoided. Alternatively, solutions of optionally substituted dimethyltryptamine compounds are frozen.
- the inventors have found that when a buffer, which is separate to the salt, is used, the resultant formulations are more stable than formulations prepared without a buffer separate to the salt.
- a container adapted to prevent penetration of ultraviolet light is used, the resultant formulations are more stable than those stored in containers that allow for ultraviolet light penetration.
- the invention provides a formulation of the first aspect or kit of the second aspect for use as a medicament or for use in combination with psychotherapy.
- the invention provides a formulation of the first aspect or kit of the second aspect for use in a method of treating a psychiatric or neurological disorder in a patient.
- the invention provides a method of treating a psychiatric or neurological disorder comprising administering to a patient in need thereof a formulation of the first aspect.
- the invention provides a method of treating a psychiatric disorder comprising administering to a patient in need thereof a formulation of the first aspect in combination with psychotherapy.
- the invention provides an aqueous pharmaceutical formulation comprising a salt comprising a Bransted acid having a pKa at 25 °C of from about 3 to about 5, and a compound of Formula IA wherein:
- R 1a is independently selected from -R 4a , -OH, -OR 4a , -O(CO)R 4a , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2a is C( xa H) 3 ;
- R 3a is C( xa H) 3 ; each R 4a is independently selected from C1-C4alkyl; and each xa H and ya H is independently selected from protium or deuterium; and water, with a pH from about 5 to about 6.5, and a concentration of the compound of Formula IA of about 10 mg/ml or greater as the freebase equivalent salt.
- the formulation may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- the pharmaceutical formulation comprises an effective dose of a compound of Formula IA for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the invention provides an aqueous pharmaceutical formulation comprising a salt comprising a Bransted acid having a pKa at 25 °C of from about 3 to about 5, and a compound of Formula IB
- R 1b is independently selected from -R 4b , -OH, -OR 4b , -O(CO)R 4b , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2b is C( xb H) 3 ;
- R 3b is C( xb H) 3 ; each R 4b is independently selected from Ci-C 4 alkyl; and each xb H, yb H and Z H is independently selected from protium or deuterium: and water, with a pH from about 5 to about 6.5, and a concentration of the compound of Formula IB of about 10 mg/ml or greater as the freebase equivalent salt.
- the formulation may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- the pharmaceutical formulation comprises an effective dose of a compound of Formula IB for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- a compound of Formula IB for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the invention provides a lyophilised powder formulation comprising a formulation as defined in the first aspect of the invention which has been lyophilised.
- the invention provides a method of preparing a lyophilised powder formulation comprising drying the formulation as defined in the first aspect of the invention by lyophilisation.
- the invention provides a method of preparing an aqueous formulation comprising mixing the lyophilised powder formulation as defined in the tenth aspect or as prepared in the method of the eleventh aspect into water to provide a formulation comprising the salt of an optionally substituted dimethyltryptamine compound, the base agent, water, and optionally the buffer which is separate to the salt to provide a formulation having a pH of from about 5 to about 6.5, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg.
- the formulation may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- embodiments of the first aspect of the invention apply mutatis mutandis to the tenth, eleventh and twelfth aspects of the invention.
- Figure 1 Figure 1A and 1 B show plots of the mean plasma N,N-
- Dimethyltryptamine SPL026), d2- N,N-Dimethyltryptamine (SPL028i) and da- N,N- Dimethyltryptamine (SPL028viii) concentration over time following 3.5mg/kg (as fumarate) IM dose; added as a cassette in vivo.
- Figure 1A Linear plot
- Figure 1B Semi-log plot. All three drug substances achieve a Cmax greater than 50 ng/ml, indicative of a therapeutically relevant dose.
- SPL028i and SPL028viii each demonstrate significantly higher plasma levels at 30 mins compared with undeuterated DMT.
- Figure 2A and 2B show plots of the mean plasma d2-DMT (SPL028i) concentration over time following 3.5mg/kg and lOmg/kg (as fumarate) IM doses in vivo.
- Figure 2A Linear plot
- Figure 2B Semi-log plot
- SEM error bars plots of the mean plasma d2-DMT (SPL028i) concentration over time following 3.5mg/kg and lOmg/kg (as fumarate) IM doses in vivo.
- Figure 3 shows the pH-solubility curve for N,N-dimethyltryptamine from pH 4 to pH 10.
- aqueous refers to a formulation that comprises water and may also comprise additional solvents.
- the formulations of the invention are useful in therapy and may be administered to a patient in need thereof.
- the term ‘patient’ preferably refers to a mammal. Typically, the mammal is a human, but may also refer to a domestic mammal. The term does not encompass laboratory mammals.
- the term ‘effective does’ refers to a dose which, on average, elicits a clinical response, i.e. an improvement in symptoms.
- the term ‘in combination with psychotherapy’ refers to the treatment of a psychiatric disorder by psychological means, which are enhanced by administration of a formulation of the invention.
- the terms ‘psychedelic assisted therapy’ and ‘pharmacological assisted therapy’ are used herein to refer to treatment in combination with psychotherapy.
- treatment defines the therapeutic treatment of a patient, in order to reduce or halt the rate of progression of a disorder, or to ameliorate or cure the disorder.
- Prophylaxis of a disorder as a result of treatment is also included. References to prophylaxis are intended herein not to require complete prevention of a disorder: its development may instead be hindered through treatment in accordance with the invention.
- treatment is not prophylactic, and the formulation is administered to a patient having a diagnosed or suspected disorder.
- psychiatric or neurological disorders are disorders which may be associated with one or more cognitive impairment.
- the term ‘psychiatric disorder’ is a clinically significant behavioural or psychological syndrome or pattern that occurs in an individual and that is associated with present distress (e.g., a painful symptom) or disability (i.e., impairment in one or more important areas of functioning) or with a significantly increased risk of suffering death, pain, disability, or an important loss of freedom.
- psychedelic assisted therapy is defined as any psychological therapeutic practice that is provided alongside a psychedelic therapeutic formulation, including for example any formulation defined by the present invention.
- OCD anti-compulsive disorder
- An obsession is defined as an unwanted intrusive thought, image or urge that repeatedly enters the person’s mind.
- Compulsions are repetitive behaviours or mental acts that the person feels driven to perform.
- OCD manifests as one or more obsessions, which drive adoption of a compulsion.
- an obsession with germs may drive a compulsion to clean or an obsession with food may drive a compulsion to overeat, eat too little or throw up after eating (i.e. an obsession with food may manifest itself as an eating disorder).
- a compulsion can either be overt and observable by others, such as checking that a door is locked, or a covert mental act that cannot be observed, such as repeating a certain phrase in one’s mind.
- the term ‘eating disorder’ is defined by severe and persistent disturbance in eating behaviours and associated distressing thoughts and emotions.
- the term ‘eating disorder’ includes anorexia nervosa and bulimia nervosa, binge eating disorder, avoidant restrictive food intake disorder, other specified feeding and eating disorder, pica and rumination disorder.
- the invention provides a formulation or kit according to the first and second aspect of the invention for use in a method of treating an eating disorder.
- the term ‘eating disorder’ includes anorexia nervosa, bulimia and binge eating disorder (BED).
- the symptoms of anorexia nervosa include eating too little and/or exercising too much in order to keep weight as low as possible.
- the symptoms of bulimia include eating a lot of food in a very short amount of time (i.e. binging) and then being deliberately sick, using laxatives, eating too little and/or exercising too much to prevent weight gain.
- the symptoms of BED include regularly eating large portions of food until uncomfortably full, and consequently feeling upset or guilty.
- depression includes major depressive disorder, persistent depressive disorder, bipolar disorder, bipolar depression, and depression in terminally ill patients.
- major depressive disorder (MDD, also referred to as major depression or clinical depression) is defined as the presence of five or more of the following symptoms over a period of two-weeks or more (also referred to herein as a ‘major depressive episode’), most of the day, nearly every day:
- depressed mood such as feeling sad, empty or tearful (in children and teens, depressed mood can appear as constant irritability);
- At least one of the symptoms must be either a depressed mood or a loss of interest or pleasure.
- Persistent depressive disorder also known as dysthymia
- dysthymia is defined as a patient exhibiting the following two features:
- A. has depressed mood for most the time almost every day for at least two years. Children and adolescents may have irritable mood, and the time frame is at least one year.
- treatment resistant major depressive disorder describes MDD that fails to achieve an adequate response to an adequate treatment with standard of care therapy.
- bipolar disorder also known as manic-depressive illness, is a disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks.
- bipolar disorder There are two defined sub-categories of bipolar disorder; all of them involve clear changes in mood, energy, and activity levels. These moods range from periods of extremely ‘up,’ elated, and energised behaviour (known as manic episodes, and defined further below) to very sad, ‘down,’ or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.
- Bipolar I Disorder defined by manic episodes that last at least 7 days, or by manic symptoms that are so severe that the person needs immediate hospital care. Usually, depressive episodes occur as well, typically lasting at least 2 weeks. Episodes of depression with mixed features (having depression and manic symptoms at the same time) are also possible.
- Bipolar II Disorder defined by a pattern of depressive episodes and hypomanic episodes, but not the full-blown manic episodes described above.
- bipolar depression is defined as an individual who is experiencing depressive symptoms with a previous or coexisting episode of manic symptoms, but does not fit the clinical criteria for bipolar disorder.
- anxiety disorder includes generalised anxiety disorder, phobia, panic disorder, social anxiety disorder, and post-traumatic stress disorder.
- GAD Generalised anxiety disorder
- GAD means a chronic disorder characterised by long-lasting anxiety that is not focused on any one object or situation. Those suffering from GAD experience non-specific persistent fear and worry, and become overly concerned with everyday matters. GAD is characterised by chronic excessive worry accompanied by three or more of the following symptoms: restlessness, fatigue, concentration problems, irritability, muscle tension, and sleep disturbance.
- Phobia is defined as a persistent fear of an object or situation the affected person will go to great lengths to avoid, typically disproportional to the actual danger posed. If the feared object or situation cannot be avoided entirely, the affected person will endure it with marked distress and significant interference in social or occupational activities.
- a patient suffering from a ‘panic disorder’ is defined as one who experiences one or more brief attack (also referred to as a panic attack) of intense terror and apprehension, often marked by trembling, shaking, confusion, dizziness, nausea, and/or difficulty breathing.
- a panic attack is defined as a fear or discomfort that abruptly arises and peaks in less than ten minutes.
- Social anxiety disorder is defined as an intense fear and avoidance of negative public scrutiny, public embarrassment, humiliation, or social interaction. Social anxiety often manifests specific physical symptoms, including blushing, sweating, and difficulty speaking.
- Post-traumatic stress disorder is an anxiety disorder that results from a traumatic experience. Post-traumatic stress can result from an extreme situation, such as combat, natural disaster, rape, hostage situations, child abuse, bullying, or even a serious accident. Common symptoms include hypervigilance, flashbacks, avoidant behaviours, anxiety, anger and depression.
- post-partum depression PPD, also known as postnatal depression
- Symptoms typically develop within 4 weeks of delivery of the baby and often include extreme sadness, fatigue, anxiety, loss of interest or pleasure in hobbies and activities, irritability, and changes in sleeping or eating patterns.
- substance abuse means a patterned use of a drug in which the user consumes the substance in amounts or with methods that are harmful to themselves or others.
- the term ‘gambling disorder’ means persistent and recurrent problematic gambling behaviour leading to clinically significant impairment or distress.
- the disorder has similarities with substance abuse.
- an avolition disorder refers to a disorder that includes as a symptom the decrease in motivation to initiate and perform self-directed purposeful activities.
- the invention provides an aqueous pharmaceutical formulation suitable for either intramuscular injection and/or nebulised inhalation, comprising a salt of an optionally substituted dimethyltryptamine compound; a base agent; water; and optionally a buffer which is separate to the salt; wherein the formulation has a pH of from about 5 to about 6.5, and an osmolality of from about 250 to about 350 mOsm/Kg.
- the formulation may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- the pharmaceutical formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the inventors have found that the formulation is surprisingly more stable than formulations prepared at higher pH (specifically those prepared at a pH matching human blood serum, i.e. at a pH of about 7.4).
- the greater stability of the formulation of the invention relative to the isotonic formulation is discussed in more detail in the Examples section.
- Osmolality is formally defined as the quotient of the negative natural logarithm of the rational activity of water and the molar mass of water, as represented by formula: where p is the partial vapour pressure of water in the solution and p* is the partial vapour pressure of pure water.
- osmolality is the number of osmotically active particles (the number of solute particles) in 1 kg of a solution.
- osmolality is a function only of the number of particles, and is not related to particle molecular weight, size, shape, or charge (see D. K. Faria et al., M. E. Mendes and N. M. Sumita, J. Bras. Patol. Med.
- one mole of a nondissociating substance e.g. DMT as a free base
- osmolality 1 Osm/kg
- a substance that dissociates into two separate species in solution e.g. DMT fumarate
- first solution is defined herein to be isotonic with a second solution
- the solutions have the same osmolality.
- a formulation is defined to be isotonic with human blood serum
- the formulation has the same osmolality as human blood serum.
- Human blood serum typically has an osmolality of about 275 to about 300 mOsm/Kg (L. Hooper et al., BMJ Open, 2015; 5(10): e008846).
- the formulation of the invention is suitable for nebulised inhalation.
- the particles present in the formulation for nebulised inhalation have a mass mean aerodynamic diameter (MMAD) of from about 0.1 to about 10 pm, preferably from about 0.3 to about 8 pm, preferably from about 0.3 to about 7 pm, more preferably from about 0.5 to about 5 pm or from about 3 to about 7 pm.
- the MMAD will be selected according to the type of nebuliser, such as a jet nebuliser, mesh nebuliseror an ultrasonic nebuliser.
- a multistage cascade impactor (Cl) apparatus may be used to size fractionate aerosols in terms of their aerodynamic particle size distributions (APSDs).
- the MMAD is calculated from the APSD and is defined as the diameter at which 50% of the particles of an aerosol by mass are larger and 50% are smaller.
- the formulation (i.e. of the invention) is suitable for intramuscular injection, by which is meant that it is in accordance with Pharmacopeial requirements of sterility, contaminants, and pyrogens (see for example The United States Pharmacopeial Convention, General Requirements I (1) Injections, page 33).
- the formulation contains inhibitors of the growth of microorganisms (e.g. antimicrobial preservatives) and/or anti-oxidants.
- Formulations suitable for parenteral administration generally have a pH of about 3 to 9 and an osmolality of about 250 to about 600 mOsm/Kg. pH values above 9 are reported by I. Usach etal. in Adv. Ther., 36, 2986-2996 (2019) to relate to tissue necrosis (death of cells within the tissue), whereas values lower than 3 are reported to cause pain and phlebitis (inflammation of veins). However, Usach et al report ‘a pH close to the physiological one is recommended to minimize pain, irritation, and tissue damage' (emphasis added). Osmolality values greater than 600 mOsm/Kg are also reported to cause pain. Usach et al also recommend that parenteral formulations should be formulated as isotonic solutions (osmolality of about 300 mOsm/Kg), proposing an upper limit of 600 mOsm/Kg to minimise pain.
- the formulation (i.e. of the invention) is also suitable for inhalation, particularly for nebulised inhalation.
- the formulation comprises a salt of an optionally substituted dimethyltryptamine compound.
- Formulations in accordance with this invention may comprise one or more than one salt of an optionally substituted dimethyltryptamine compound.
- formulations comprise an optionally substituted dimethyltryptamine salt when they comprise ions of an optionally substituted dimethyltryptamine compound and ions that counter the charge of the optionally substituted dimethyltryptamine ions (counterions).
- the optionally substituted dimethyltryptamine salt within the formulation may be formed, for example, by contacting optionally substituted dimethyltryptamine as a free base with an aqueous solution comprising an excess of buffer relative to the molar quantity of optionally substituted dimethyltryptamine.
- the dimethyltryptamine compound is optionally substituted with deuterium, wherein a deuterium atom is a hydrogen atom with an additional neutron.
- the dimethyltryptamine compound is substituted at position 4 or 5 with acetoxy or methoxy or at position 4 with monohydrogen phosphate.
- acetoxy (often abbreviated to OAc) defines a univalent group derived from acetic acid by removal of a hydrogen atom from the OH moiety.
- methoxy (often abbreviated to OMe) defines a univalent group derived from methanol by removal of a hydrogen atom from the OH moiety.
- monohydrogen phosphate defines a divalent group of formula HPO4, derived from phosphoric acid by removal of a proton from two of the three OH moieties, and thus denotes a substituent of formula - OP(O)(OH)O-.
- psilocybin also known as [3-(2- Dimethylaminoethyl)-1H-indol-4-yl] dihydrogen phosphate
- monohydrogen phosphate at the 4-position, this generally being understood to be the predominant form owing to the pKa values of the two terminal phosphate oxygen atoms being estimated as 1.3 and 6.5.
- the monohydrogen phosphate-containing form of psilocybin exists as a zwitterion (i.e. an internal salt) in which the nitrogen atom of the dimethylamino moiety is protonated.
- psilocybin is to be regarded as, a salt of a dimethyltryptamine compound substituted at position 4 with monohydrogen phosphate.
- positions 4 and 5 of the optionally substituted dimethyltryptamine salt refer to the positions labelled in the structure below (substitution not shown).
- the formulation optionally comprises a buffer, which is separate to the salt, i.e. the buffer is not merely a counterion to the optionally substituted dimethyltryptamine.
- a buffer which is separate to the salt, i.e. the buffer is not merely a counterion to the optionally substituted dimethyltryptamine.
- the salt is N,N-dimethyltryptamine fumarate (i.e. the fumaric acid salt of N,N-dimethyltryptamine)
- an amount of buffer may be required over and above the buffer effect provided by the fumarate salt.
- buffer is well known in the art and refers to a chemical which, on inclusion within a formulation, resists a change in pH on addition of acid or base to the formulation.
- the term ‘buffer’ refers to the buffer system or the buffer agent.
- Suitable buffer systems for use in the formulations of the invention comprise a weak acid and its conjugate base.
- a suitable buffer system comprises an acid with a pKa value that lies within ⁇ 1 of the desired pH of the formulation. For example, if the desired pH of the formulation is about 5.0, a suitable buffer system comprises a weak acid with a pKa value of from about 4.0 to about 6.0. If the acid of a buffer system has more than one pKa value (i.e. each molecule of the acid is able to donate more than one proton), in order for the buffer to be suitable, at least one of the pKa values lies within the desired pH range.
- the weak acid and conjugate base of the buffer system are in equilibrium with one another.
- a constraint such as a change in concentration of a reactant
- addition of acid or base to the formulation shifts the position of equilibrium in favour of the conjugate base or weak acid, respectively. Consequently, the concentration of free protons in the formulation (and thus the pH) is relatively unchanged.
- the formulation of the invention has a pH of from about 5 to about 6.5, preferably from about 5 to about 6, preferably from about 5.0 to about 6.0.
- the pH is from 5 to 6, preferably from 5.0 to about 6.0.
- the pH is from about 5.2 to about 5.8, or about 5.5 to 6.0.
- the pH is from about 5.7 to about 6.5, or about 5.7 to about 6. More preferably, the pH is about 5.5 or about 6.
- the formulation comprises a buffer.
- the buffer is separate to the salt.
- the pKa values cited herein are those reported at 25 °C in water.
- the buffer system comprises only one of the pairs listed above, i.e. one acid and its conjugate base.
- the buffer system comprises an acetate salt and acetic acid; a citrate salt and citric acid; or a phosphate salt and phosphoric acid.
- the buffer system comprises an acetate salt and acetic acid; or a citrate salt and citric acid.
- the buffer system comprises an acetate salt and acetic acid, often sodium acetate and acetic acid, or potassium acetate and acetic acid.
- buffer agent refers to the weak acid or weak base. Any pharmaceutically acceptable buffer agent may be used in the formulations of the invention, including phosphoric acid, citric acid, acetic acid, phosphate salt, citrate salt, and acetate salt. In some embodiments, the buffer comprises sodium phosphate, sodium citrate, or sodium acetate.
- the pharmaceutical formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use as a medicament or for use in psychedelic assisted therapy, meaning that the formulation comprises the salt of the dimethyltryptamine compound in a dose range which elicits a psychedelic experience in an average weight human patient.
- the dose range is from about 5 to about 250 mg, or about 10 to about 150mg, suitably from about 10 to about 100 mg, suitably from about 20 to about 100 mg (as free base equivalent).
- the dose range is from about 20 to about 70 mg, or from about 20 to about 50 mg.
- the suitable dose is about 9 mg, or about 12 mg, or about 17 mg, or about 21.5 mg, or about 24 mg, or about 30.5 mg, or about 34 mg, or about 33 mg, or about 36 mg, or about 38.5 mg, or about 43 mg, or about 51 mg, or about 52 mg, or about 55 mg, or about 60 mg, or about 64.5 mg.
- the dose ranges and suitable doses provided in this paragraph refer to the free base equivalent dose.
- the concentration of buffer within the formulation is typically sufficient to resist significant pH change of the formulation on storage of the formulation for two weeks (i.e. the pH typically fluctuates less than about 0.1 pH unit), while also ensuring that the osmolality of the formulation lies within the desired range of from about 250 to about 350 mOsm/Kg.
- the skilled person is able to assess suitable buffer concentrations and to achieve this.
- the concentration of buffer is from about 15 mM to about 75 mM, such as about 20 mM to about 30 mM. In some embodiments, the concentration of the buffer is about 25 mM.
- the formulation comprises a salt of an optionally substituted dimethyltryptamine compound at a concentration of about 10 mg/ml or greater as the freebase equivalent.
- the salt comprises an acid and the optionally substituted dimethyltryptamine compound, or the salt comprises a dimethyltryptamine compound substituted with monohydrogen phosphate, preferably at position 4 of the indole ring system.
- An example of a salt comprising an acid and dimethyltryptamine compound is N,N- dimethyltryptamine fumarate, which is the fumaric acid salt of N,N-dimethyltryptamine.
- P. H. Stahl and C. G. Wermuth provide an overview of pharmaceutical salts and the acids comprised therein in Handbook of Pharmaceutical Salts: Properties, Selection and Use, Weinheim/Zurich:Wiley-VCH/VHCA, 2002. The acids described in this review are suitable acids for inclusion within the salt of the formulation.
- the salt may comprise an acid selected from the group consisting of fumaric acid, tartaric acid, citric acid, acetic acid, lactic acid, gluconic acid, 1 -hydroxy- 2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4- acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, decanoic acid, hexanoic acid, octanoic acid, carbonic acid, cinnamic acid, cyclamic acid, dodecylsulfuric acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid,
- the acid is a Bransted acid having a pKa at 25 °C in water of from about 3 to about 5.
- the Bransted acid may act both as a counterion to the dimethyltryptamine compound and as a buffer.
- the formulation may be stabilised to a greater extent, i.e. degradation of the dimethyltryptamine compound may be further ameliorated, when the salt comprises such an acid.
- the salt comprises a Bransted acid having a pKa at 25 °C of from about 3 to about 5, and a compound of Formula IA wherein:
- R 1a is independently selected from -R 4a , -OH, -OR 4a , -O(CO)R 4a , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2a is C( xa H) 3 ;
- R 3a is C( xa H) 3 ; each R 4a is independently selected from Ci-C 4 alkyl; and each xa H and ya H is independently selected from protium or deuterium.
- the salt comprises a Bransted acid having a pKa at 25 °C of from about 3 to about 5, and a compound of Formula IB wherein: R 1b is independently selected from -R 4b , -OH, -OR 4b , -O(CO)R 4b , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2b is C( xb H) 3 ;
- R 3b is C( xb H) 3 ; each R 4b is independently selected from Ci-C 4 alkyl; and each xb H, yb H and Z H is independently selected from protium or deuterium.
- the compound is of (i) Formula IA, wherein each R 1a is independently selected from -OR 4a , -O(CO)R 4a , monohydrogen phosphate and -OH, or (ii) Formula IB, wherein each R 1b is independently selected from -OR 4b , -O(CO)R 4b , monohydrogen phosphate and -OH.
- Formula IA is a sub-formula of IB, wherein each Z H is hydrogen.
- the compound is of (i) Formula IA, wherein R 4a is methyl, or (ii) Formula IB, wherein R 4b is methyl.
- the compound is of Formula IA or Formula IB according to any preceding embodiment, wherein n is 1 , 2, 3, or 4.
- the compound is of Formula IA or Formula IB according to any preceding embodiment, wherein n is 1.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein n is 0; or n is 1 , and R 1a is at the 4- or 5-position; or (ii) Formula IB according to any preceding embodiment, wherein n is 0; or n is 1 , and R 1b is at the 4- or 5-position.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein each R 1a is independently selected from -OH, -OMe, - OCD 3 , -OAC, -O(CO)Me, and monohydrogen phosphate; or (ii) Formula IB, wherein each R 1b is independently selected from -OH, -OMe, -OCD 3 , -OAc, -O(CO)Me, and monohydrogen phosphate.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein n is 0; or n is 1 and R 1a is selected from 5-methoxy, 5- bromo, 4-acetoxy, 4-monohydrogen phosphate, 4-hydroxy and 5-hydroxy; or (ii) Formula IB according to any preceding embodiment, wherein n is 0; or n is 1 and R 1b is selected from 5-methoxy, 5-bromo, 4-acetoxy, 4-monohydrogen phosphate, 4-hydroxy and 5-hydroxy.
- the compound is of Formula IA or IB, wherein n is 0. In some embodiments, the compound is of (i) Formula IA according to any preceding embodiment, wherein both ya H are deuterium, or (ii) Formula IB according to any preceding embodiment, wherein both yb H are deuterium.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein both ya H are protium, or (ii) Formula IB according to any preceding embodiment, wherein both yb H are protium.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein one ya H is protium and one ya H is deuterium, or (ii) Formula IB according to any preceding embodiment, wherein one yb H is protium and one yb H is deuterium.
- the compound is of Formula IB, wherein both Z H are deuterium. In some embodiments, the compound is of Formula IB, wherein both Z H are protium. In some embodiments, the compound is of Formula IB, wherein one Z H is protium and one Z H is deuterium.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein each xa H is D, or (ii) Formula IB according to any preceding embodiment, wherein each xb H is D.ln some embodiments, the compound is of (i) Formula IA according to any preceding embodiment, wherein R 2a and R 3a are both C( xa H) 3 , or (ii) Formula IB according to any preceding embodiment, wherein R 2b and R 3b are both C( xb H) 3 .
- the compound is of (i) Formula IA according to any preceding embodiment, wherein both C( xa H) 3 are the same, or (ii) Formula IB according to any preceding embodiment, wherein both C( xb H) 3 are the same.
- the compound is of (i) Formula IA according to any preceding embodiment, wherein both R 2a and R 3a are CD 3 , or (ii) Formula IB according to any preceding embodiment, wherein both R 2b and R 3b are CD 3 .
- the compound is of (i) Formula IA according to any preceding embodiment, wherein both R 2a and R 3a are CH 3 , or (ii) Formula IB according to any preceding embodiment, wherein both R 2b and R 3b are CH 3 .
- the compound is of (i) Formula IA according to any preceding embodiment, wherein R 2a is CD 3 and R 3a is CH 3 , or (ii) Formula IB according to any preceding embodiment, wherein R 2b is CD 3 and R 3b is CH 3 .
- Ci-C 4 alkyl may be a deuterated Ci-C 4 alkyl, for example CD 3 .
- certain optionally substituted dimethyltryptamine compounds comprised in the present invention include compounds which are known by two or more names in the art, including:
- N,N-dimethyltryptamine may also be known as N,N- dimethyl-1 H-indole-3-ethanamine (CAS number 61-50-7).
- the compound 5-methoxy-N,N-dimethyltryptamine may also be known as 5-methoxy-N,N-dimethyl-1 H-indole-3-ethanamine (CAS number 1019-45-0).
- the compound 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT) may also be known as 4-acetoxy-N,N-dimethyltryptamine, O-acetylpsilocin, psilacetin, or [3-[2- (dimethylamino)ethyl]-1 H-indol-4-yl] acetate (CAS number 92292-84-7).
- the compound 4-hydroxy-N,N-dimethyltryptamine-d6 may also be known as psilocin-d 6 or 3-(2-(£>/s(methyl-d 3 )amino)ethyl)-1 H-indol-4-ol.
- the compound N,N-di(trideuteromethyl)tryptamine may also be known as /V,/V- hexadeuterio-dimethyltryptamine or D 6 -DMT.
- the compound 5-hydroxy-/V-mono(trideuteromethyl)tryptamine may also be known as /V-methyl-serotonin-D 3 (CAS No. 1794811-18-9).
- the compound /V-mono(trideuteromethyl)tryptamine may also be known as /V- methyl-tryptamine-D 3 (CAS No. 1794745-39-0).
- the compound a, a -dideutero-N,N-dimethyltryptamine may also be known as D 2 - DMT, or 2-(1 H-indol-3-yl)-N,N-dimethylethan-1-amine-1 ,1-d 2 .
- the compound a,a,p,p-tetradeutero-N,N-dimethyltryptamine may also be known as D 4 -DMT, or 2-(1 H-indol-3-yl)-N,N-dimethylethan-1-amine-1 ,1 ,2,2-d 4 .
- 3-tetradeutero-N,N-di(trideuteromethyl)tryptamine may also be known as D10-DMT, or 2-(1 H-indol-3-yl)-N,N-bis(methyl-d 3 )ethan-1-amine- 1 ,1 ,2,2-d 4 .
- the optionally substituted dimethyltryptamine compound is N,N-dimethyltryptamine. In some embodiments, the optionally substituted dimethyltryptamine compound is a deuterated dimethyltryptamine compound, including a,a-dideutero-N,N-dimethyltryptamine, N,N-di(trideuteromethyl)tryptamine, a,a- dideutero-N,N-di(trideuteromethyl)tryptamine, a,a,p,
- Salts of deuterated /V,/V-dimethyltryptamine compounds which as defined above can be synthesised following the synthetic schemes disclosed in WO 2020/245133 A1 , WO 2021/116503 and WO 2021/089873 A1 (all Small Pharma Ltd), have been found to be particularly advantageous drug substances for formulations of the present invention.
- Deuterated /V,/V-dimethyltryptamine compounds as described hereinabove have been found to exhibit a kinetic isotope effect which can be used to extend their half-life in biological systems.
- formulations of the present invention comprising deuterated N,N-di methyltryptamine compounds and deuterated substituted /V,/V-dimethyltryptamine compounds have significantly higher Cmax and exposure relative to their undeuterated analogue (see figures 1A and 1 B).
- compositions may be prepared for use in the formulations of the invention comprising amounts of N,N-dimethyltryptamine and deuterated N,N- dimethyltryptamine compounds, wherein the relative proportions of N,N- dimethyltryptamine against deuterated N,N-dimethyltryptamine compounds (as defined above) may be controlled by varying the ratio of lithium aluminium hydride and lithium aluminium deuteride in the reducing agent, as described in WO 2021/116503 (Small Pharma Ltd), for example.
- composition comprising amounts of N,N-dimethyltryptamine and/or deuterated N,N-dimethyltryptamine compounds may be used to provide the salt of an optionally substituted dimethyltryptamine compound, such that the formulation comprises one or more optionally substituted dimethyltryptamine compounds each in the form of a salt as described herein.
- compositions comprised in the formulation may comprise an amount of 90% or greater, 95% or greater, preferably 97% or greater, more preferably 98% or greater, most preferably 99% or greater, a,a-dideutero-N,N-dimethyltryptamine by weight of the composition.
- compositions comprised in the formulation may comprise an amount of 5% or less, preferably 2% or less, more preferably 1% or less, most preferably 0.5% or less, N,N-dimethyltryptamine by weight of the composition.
- compositions comprised in the formulation may comprise an amount of 5% or less, preferably 2% or less, more preferably 1% or less, most preferably 0.5% or less, a-protio-a-deutero-N,N-dimethyltryptamine by weight of the composition.
- the compositions comprised in the formulation may comprise a) 90% or greater of an a,a-dideutero-N,N-dimethyltryptamine compound, b) 10% or less of an a-protio-a-deutero-N,N-dimethyltryptamine compound, and c) 2% or less of N,N-dimethyltryptamine by weight of the composition, wherein the weight of the a,a-dideutero-N,N-dimethyltryptamine compound, the a-protio-a-deutero-N,N- dimethyltryptamine compound, and N,N-dimethyltryptamine total 100%.
- the compositions comprised in the formulation may comprise a) 95% or greater of an a,a-dideutero-N,N-dimethyltryptamine compound, b) 5% or less of an a-protio-a-deutero-N,N-dimethyltryptamine compound, and c) 1% or less of N,N-dimethyltryptamine by weight of the composition, wherein the weight of the a,a-dideutero-N,N-dimethyltryptamine compound, the a-protio-a-deutero-N,N- dimethyltryptamine compound, and N,N-dimethyltryptamine total 100%.
- N,N-dimethyltryptamine may be absent, or may be present in the composition in trace amounts, or may be present in the composition in an amount 2% or less by weight of the composition, or in an amount 1% or less by weight of the composition.
- the 2% or less, or 1% or less N,N-dimethyltryptamine referred to above should be understood to encompass, for example undeuterated 4, 5, 6 or 7-substituted N,N-dimethyltryptamines such as 5-methoxy-N,N-dimethyltryptamine.
- 5-methoxy-N,N-dimethyltryptamine may be absent, or may be present in the composition in trace amounts, or may be present in the composition in an amount 2% or less, or 1% or less, by weight of the composition.
- an a,a-dideutero-N,N-dimethyltryptamine compound comprises the compound a,a-dideutero-N,N-dimethyltryptamine (d 2 -DMT) as well as a,a-dideutero-N,N-dimethyltryptamine compounds comprising deuteration at other positions, such as a,a,p,p-tetradeutero-N,N-dimethyltryptamine (d 4 -DMT), a,a- dideutero-N,N-di(trideuteromethyl)tryptamine (d 8 -DMT), a,a,p,
- an a-protio-a-deutero-N,N-dimethyltryptamine compound comprises the compound a-protio-a-deutero-N,N-dimethyltryptamine (di-DMT) as well as a-protio-a-deutero-N,N-dimethyltryptamine compounds comprising deuteration at other positions, such as a-protio-a,p,p-trideutero-N,N-dimethyltryptamine (d 3 -DMT), a-protio-a-deutero-N,N-di(trideuteromethyl)tryptamine (d 7 -DMT), a-protio- a,p,p-trideutero-N,N-di(trideuteromethyl)tryptamine (d 9 -DMT), and substituted a-protio- a-deutero-N,N-
- the compositions comprised in the formulation may comprise a) 90% or greater of an optionally substituted N,N- di(trideuteromethyl)tryptamine compound, preferably 95% or greater.
- the optionally substituted N,N-di(trideuteromethyl)tryptamine compound may be N,N- di(trideuteromethyl)tryptamine (de-DMT), a,a-dideutero-N,N- di(trideuteromethyl)tryptamine (d 8 -DMT), a,a,B,B-tetradeutero-N,N- di(trideuteromethyl)tryptamme (dio-DMT), 5-methoxy-N,N- di(trideuteromethyl)tryptamine, 5-methoxy-a,a-dideutero-N,N- di(trideuteromethyl)tryptamine and 5-methoxy-a,a,p,
- the salt is of an optionally substituted dimethyltryptamine compound and an acid selected from the group consisting of fumaric acid, tartaric acid, citric acid, acetic acid, lactic acid and gluconic acid, typically fumaric acid.
- the salt may comprise: any one or a combination of N,N-dimethyltryptamine, a-monodeutero-N,N- dimethyltryptamine, a,a-dideutero-N,N-dimethyltryptamine, a,
- 4-monohydrogen phosphate-N,N-di(trideuteromethyl)tryptamine 4-monohydrogen phosphate-a,a-dideutero-N,N-di(trideuteromethyl)tryptamine, and 4-monohydrogen phosphate-a,a,p,p-tetradeutero-N,N-di(trideuteromethyl)tryptamine; and an acid selected from the group consisting of fumaric acid, tartaric acid, citric acid, acetic acid, lactic acid and gluconic acid, typically fumaric acid.
- the salt is dimethyltryptamine fumarate, i.e. it comprises dimethyltryptamine as the optionally substituted dimethyltryptamine compound and fumaric acid.
- the dimethyltryptamine compound may have a purity of about 80 to 100 %. Sometimes, the purity is about 90 to 100 %, such as from about 95 to 100 %. Typically, the dimethyltryptamine compound has a purity of from about 99 to 100 %, i.e. a purity greater than or equal to 99%. Percentages of purity herein are as determined by HPLC.
- drug substance comprising the optionally substituted dimethyltryptamine compound or salt thereof with a purity of greater than 99%.
- drug substance is meant, as is understood in the art, an active ingredient intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the patient concerned, but does not include intermediates used in the synthesis of such ingredient. It will be understood that the drug substance may comprise one or more such active ingredients.
- Preferred embodiments of any aspect of the present invention comprise a drug substance comprising an optionally substituted dimethyltryptamine compound or salt thereof having a purity of greater than or equal to 99% when measured by HPLC.
- Particularly preferred embodiments comprise a drug substance comprising an optionally substituted dimethyltryptamine compound or salt thereof having a purity of greater than or equal to 99.5%, even more preferably 99.7%, and even more preferably 99.9%, when measured by HPLC.
- the concentration of the salt of the optionally substituted dimethyltryptamine compound within the formulation may be any desired concentration to achieve greater than or equal to 10 mg/ml freebase-equivalent, provided that the osmolality of the formulation is from about 250 to about 350 mOsm/Kg.
- the dimethyltryptamine compound may be at a concentration of greater than 20 mg/mL.
- a concentration of 28 mg/mL of dimethyltryptamine provides approximately 148 mOsm/kg (approximately 296 mOsm/kg with counterions taken into account). This allows for the provision of a further 54 mOsm/kg by other components of the formulation, such as the optional buffer.
- the salt of the dimethyltryptamine compound may be at a concentration of greater than 20 mg/mL, greater than 25 mg/mL, greater than 30 mg/mL, greater than 40 mg/mL, greater than 50 mg/mL, greater than 60mg/mL or greater than 70 mg/m (as the freebase equivalent).
- the optionally substituted dimethyltryptamine compound may be at a concentration of from about 10 mg/ml to about 150 mg/ml, from about 10 mg/ml to about 100 mg/ml, from about 10 mg/ml to about 80 mg/ml, from about 15 mg/ml to about 70 mg/ml, from about 15 mg/ml to about 50 mg/ml, or from about 20 mg/ml to about 40 mg/ml (as freebase equivalent).
- the optionally substituted dimethyltryptamine compound may be at a concentration of about 25 mg/ml (as freebase equivalent).
- the total dose of the salt of the optionally substituted dimethyltryptamine compound to be used in any of the fourth to sixth aspects of the invention is suitably 10 mg to about 150 mg, preferably from about 10 mg to about 120 mg, preferably from about 10 mg to about 100 mg, preferably from about 10 mg to about 80 mg.
- the formulation of the invention has an osmolality of from about 250 to about 350 mOsm/Kg. In some embodiments of the invention, the osmolality of the formulation is from about 250 to about 400 mOsm/Kg. In some embodiments, the osmolality of the formulation of the invention is from about 275 to about 325 mOsm/Kg, such as from about 280 to about 310 mOsm/Kg. Typically, the osmolality of the formulation is from about 295 to about 305 mOsm/Kg.
- the concentration of optionally substituted dimethyltryptamine salt and optional buffer in the formulation gives rise to the desired osmolality.
- the desired osmolality may be achieved by inclusion of one or more tonicity agents in the formulation.
- the formulation further comprises a tonicity agent.
- a tonicity agent is defined herein as a chemical that, on inclusion within a formulation, increases the osmolality of the formulation. As described above, the osmolality is the number of osmotically active particles (the number of solute particles) in 1 kg of a solution.
- a chemical that acts as a solute when incorporated into the formulation lies within the definition of a tonicity agent.
- the concentration of tonicity agent depends on the concentration of other components within the formulation, such as the optionally substituted dimethyltryptamine and buffer.
- concentration of tonicity agent depends on the concentration of other components within the formulation, such as the optionally substituted dimethyltryptamine and buffer.
- a tonicity agent e.g. 95 mM of sodium chloride.
- Suitable excipients for use in the formulations of the invention may be selected from the group consisting of ethanol, citric acid, trisodium citrate, benzalkonium chloride, microcrystalline cellulose, carboxymethylcellulose sodium, chlorobutanol, edetate disodium, glycerin, hydrochloric acid, methylparaben, polyethylene glycol, propylene glycol, propylparaben, saccharin sodium, sodium bicarbonate, sodium bisulphate, sodium bisulphite, sodium chloride, sodium hydroxide, sodium metabisulphite, sodium phosphate, sodium citrate, sulphuric acid, trisodium citrate, tromethamine, and mixtures thereof.
- Suitable solvents or cosolvents for use in the formulations of the invention may be selected from ethanol, polyethylene glycol, propylene glycol, and mixtures thereof.
- the formulation comprises a cosolvent.
- the formulation does not comprise a cosolvent.
- the salt of the optionally substituted dimethyltryptamine compound is a fumarate, for example N,N-dimethyltryptamine fumarate or a,a-dideutero- N,N-dimethyltryptamine fumarate, the formulation does not comprise a cosolvent.
- Suitable buffers for use in the formulations of the invention may be selected from the group consisting of phosphoric acid, citric acid, acetic acid, sodium phosphate, sodium citrate, sodium acetate, and mixtures thereof.
- citric acid may be utilised as a buffer component, a flavouring agent, or as an antioxidant.
- a pH adjuster for example hydrochloric acid, may also function as a tonicity agent.
- the tonicity agent is any one or a combination selected from the group consisting of dextrose, sodium chloride; phosphoric acid; a phosphate salt such as sodium phosphate or potassium phosphate; acetic acid; ethanol; citric acid; a citrate salt such as sodium citrate or potassium citrate; arginine; edetic acid; an edetate salt such as sodium edetate or calcium edetate; propylene glycol; sodium bicarbonate; sodium hydroxide; and hydrochloric acid;.
- the tonicity agents listed above may be used to buffer the formulation (e.g. acetate salt, acetic acid, citrate salt, citric acid, phosphate salt, phosphoric acid).
- the tonicity agent is sodium chloride or dextrose.
- the formulation comprises the tonicity agent, such as sodium chloride, at a concentration of from about 120 mM to about 140 mM, such as from about 125 mM to about 135 mM.
- concentration of the tonicity agent, such as sodium chloride, within the formulation is about 130 mM.
- the formulation consists essentially of the optionally substituted dimethyltryptamine salt, water, a base agent, optionally a buffer, and optionally a tonicity agent and/or pH adjuster.
- a base agent optionally a buffer
- a tonicity agent and/or pH adjuster optionally a tonicity agent and/or pH adjuster
- the intention behind including the optionally substituted dimethyltryptamine salt, water, the base agent, the optional buffer and the optional tonicity agent and/or pH adjuster in the formulation is to produce a pharmaceutical formulation of optionally substituted dimethyltryptamine which is suitable for both intramuscular injection and nebuliser inhalation, and which is stable for at least several weeks when stored, it will be understood that the inclusion of components that materially affect, in a detrimental manner, the stability of the formulation or its suitability for injection (e.g. its osmolality or pH), are excluded from the formulation. On the other hand, it will be understood that the presence of any components that do not materially affect, in a detrimental manner, the stability of the formulation or its suitability for injection, is included.
- Such components include anti-oxidants and antimicrobial preservatives.
- anti-oxidants and antimicrobial preservatives include anti-oxidants and antimicrobial preservatives.
- pharmaceutical excipients and their properties including those with anti-oxidant and antimicrobial properties, see P. J. Sheskey, W G Cook and C G Cable, Handbook of Pharmaceutical Excipients, Eighth Edition, Pharmaceutical Press, London 2017.
- the base agent adjusts the pH of the formulation to the required pH range, for example from pH 5 to pH 6.
- the pH of a formulation including the optionally substituted dimethyltryptamine salt, water, and a buffer is often low, e.g. less than pH 5, and so a pH adjustment with a base agent may be required.
- the skilled person is able to asses suitable base agents to adjust the pH of the solution without risk of degradation of the optionally substituted dimethyltryptamine salt.
- the base agent may be sodium hydroxide or potassium hydroxide.
- the formulation further comprises an anti-oxidant.
- Suitable anti-oxidants commonly for use in the formulations of the invention include citric acid, sodium metabisulphite and mixtures thereof.
- the formulation further comprises an antimicrobial preservative.
- antimicrobial preservatives for use in the formulations of the invention include propylparaben (n-propyl parahydroxybenzoate), benzalkonium chloride and mixtures thereof.
- the formulation has an oxygen content of less than 5 ppm, preferably less than 2 ppm, such as between 0.1 ppm and 2 ppm.
- the skilled person is able to determine the oxygen content of the formulation using any technique known in the art to be suitable, such as using a dissolved oxygen meter (e.g. a Jenway 970 Enterprise Dissolved Oxygen Meter, available from Keison Products: http://www.keison.co.uk/products/ienway/970.pdf).
- the formulation may be stored in any suitable container.
- the container may have a volume of 10 ml or less, 5 ml or less, 4 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the formulation is stored in a container adapted to prevent penetration of ultraviolet light, such as amber glass vial.
- the container within which the formulation is stored is not so adapted (and may be, for example, made of clear glass) with protection against ultraviolet light, if desired, provided by secondary packaging (for example packaging within which the receptacle containing the formulation may be placed).
- the container is airtight and the formulation is stored under an inert atmosphere, such as under nitrogen or argon, typically nitrogen.
- the formulation may be stored at room temperature, e.g. at about 20 to about 30 °C or at cooler temperatures, for example at about 2 to about 8 °C.
- it may be stored in a freezer.
- the formulation is sparged with an inert gas, such as nitrogen or argon, to reduce the oxygen content of the formulation.
- an inert gas such as nitrogen or argon
- the invention provides a kit suitable for preparing a formulation of the first aspect, said kit comprising a salt of an optionally substituted dimethyltryptamine compound; a base agent, optionally a buffer, which is separate to the salt; and optionally a tonicity agent and/or pH adjuster.
- the kit comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in pharmacological-assisted psychotherapy (psychedelic assisted therapy) within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- an optionally substituted dimethyltryptamine compound for use in pharmacological-assisted psychotherapy (psychedelic assisted therapy) within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- kit to generate a formulation of the first aspect comprising:
- a second composition comprising a base agent and optionally a buffer which is separate to the salt, and/or a tonicity agent, and/or a pH adjuster, wherein the first and second compositions are mixed with water, and the resulting mixture generates the formulation of the first aspect.
- the optionally substituted dimethyltryptamine salt of the kit may comprise a Bransted acid having a pKa at 25 °C of from about 3 to about 5, and a compound of Formula IA or Formula IB and/or the buffer may comprise an acetate salt and acetic acid.
- the optionally substituted dimethyltryptamine salt within the kit may be a solid, e.g. in a powder or crystalline form.
- the salt may be lyophilised (freeze- dried) before incorporation into the kit. Lyophilising the salt comprises freezing it in the presence of solvent (typically water) and separating the solvent from the salt by sublimation.
- the kit further comprises a tonicity agent
- the embodiments related to the optional tonicity agent of the first aspect of the invention as defined herein apply mutatis mutandis to the second aspect.
- the tonicity agent may be any one or a combination selected from the group listed above.
- the invention provides a method of preparing a pharmaceutical formulation of the first aspect.
- the method comprises contacting the optionally substituted dimethyltryptamine salt, a base agent, optionally a buffer, and optionally a tonicity agent and/or pH adjuster, with water.
- the optionally substituted dimethyltryptamine salt comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in pharmacological-assisted psychotherapy (psychedelic assisted therapy) within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the embodiments of the first aspect of the invention apply mutatis mutandis to the third aspect.
- the salt may be dimethyltryptamine fumarate;
- the buffer may comprise acetic acid and an acetate salt or phosphoric acid and a phosphate salt; and the tonicity agent may comprise sodium chloride.
- the contacting of the method may be achieved in a variety of ways.
- the optionally substituted dimethyltryptamine salt is dissolved in water to form a first solution to which the base agent and optional buffer are added and dissolved, forming a second solution. If a tonicity agent or pH adjuster is used, it is often added to and dissolved in the second solution. An additional solvent or cosolvent may be added to the first solution or second solution.
- an aqueous solution of the buffer is contacted with the salt, wherein the aqueous solution of the buffer has a pH of from about 5 to about 6.5, such as a pH from about 5 to about 6, or from about 5.3 to about 6, or from about 5.5 to about 6.
- the aqueous solution of the buffer may have a pH of from 5 to 6.
- the aqueous solution of the buffer has a pH of about 5.5 or about 6.
- the optionally substituted dimethyltryptamine salt within the formulation may be formed by contacting optionally substituted dimethyltryptamine as a free base with an aqueous solution comprising a quantity of buffer suitable to stabilise the pH and act as counterion to the optionally substituted dimethyltryptamine when protonated.
- the method of the invention may comprise contacting the optionally substituted dimethyltryptamine in free base form with a buffer, water and optionally a tonicity agent.
- the method further comprises using a base agent to adjust the pH of the solution resultant from the contacting. Since the pH of the solution resultant from the contacting step is usually low, a subsequent pH adjustment step is required. pH adjustment often comprises contacting the solution with a suitable base agent, for example a strong base agent. The skilled person is able to assess which bases are suitable to adjust the pH of the solution resultant from the contacting without risk of degradation of the optionally substituted dimethyltryptamine salt.
- the pH of the solution resultant from the contacting is adjusted with a base agent which may be a suitable alkali, preferably sodium hydroxide or potassium hydroxide.
- the pH is further adjusted with a pH adjuster in order to achieve the desired pH.
- the pH adjuster may be a suitable acid, such as an acid selected from acetic acid, aspartic acid, benzene sulphonic acid, benzoic acid, citric acid, hydrochloric acid, hydrobromic acid, methane sulphonic acid, propionic acid, tartaric acid, fumaric acid, lactic acid, phosphoric acid, maleic acid, and sulphuric acid, or mixtures thereof.
- the pH adjuster is selected from acetic acid, aspartic acid, benzene sulphonic acid, benzoic acid, citric acid, hydrochloric acid, hydrobromic acid, methane sulphonic acid, tartaric acid, fumaric acid, maleic acid, and sulphuric acid, or mixtures thereof.
- the formulations of the invention comprise a pH adjuster which is hydrochloric acid.
- the method further comprises sparging the solution resultant from the contacting with an inert gas, such as nitrogen or argon, typically nitrogen.
- the invention provides a formulation of the first aspect or the kit of the second aspect for use as a medicament, or for use in combination with psychotherapy.
- the formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in pharmacological- assisted psychotherapy, or psychedelic assisted therapy, within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the invention provides a formulation of the first aspect or a kit of the second aspect for use in a method of treating a psychiatric or neurological disorder in a patient.
- the formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in pharmacological-assisted psychotherapy or psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the psychiatric or neurological disorder is selected from the group consisting of (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) an anxiety disorder, (iv) substance abuse and gambling disorders and (v) an avolition disorder.
- the disorder is selected from the group consisting of major depressive disorder, treatment resistant major depressive disorder, post-partum depression, an obsessive compulsive disorder and an eating disorder such as a compulsive eating disorder.
- the invention provides a method of treating a psychiatric or neurological disorder comprising administering to a patient in need thereof a formulation of the first aspect.
- the formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in pharmacological-assisted psychotherapy or psychedelic assisted therapy within a volume of 5 ml or less, preferably within a volume of 4 ml or less, 3 ml or less, 2.5 ml or less, 2 ml or less, 1 ml or less, or 0.5 ml or less.
- the psychiatric or neurological disorder may be any of those described in relation to the fifth aspect.
- the disorder may be selected from the group consisting of major depressive disorder, treatment resistant major depressive disorder, post-partum depression, an obsessive compulsive disorder and an eating disorder such as a compulsive eating disorder.
- the formulation of the first aspect may be administered in combination with psychotherapy (i.e. in pharmacological-assisted psychotherapy).
- the formulation comprises an effective amount of the dimethyltryptamine compound, i.e. an amount that is sufficient to reduce or halt the rate of progression of the disorder, or to ameliorate or cure the disorder and thus produce the desired therapeutic or inhibitory effect.
- the formulation is suitable for intramuscular injection, thus its administration to a patient typically comprises injection of the formulation.
- the formulation may be suitable for bolus injection, in which a discrete amount of an optionally substituted dimethyltryptamine salt is administered in one injection such that the concentration of optionally substituted dimethyltryptamine in the body quickly increases.
- IM injections administer a dosage volume of 5 ml or less, using a 19- 27 needle gauge, more typically a 20-25 needle gauge.
- the concentrated formulations of the present invention allow the administration of lower volumes, using a higher needle gauge, suitable 22-27, which may reduce pain associated with injection.
- the injection volume may be from about 0.5 to about 4 ml, from about 0.5 to about 3 ml, or from about 0.5 to about 2.5 ml.
- the formulation is also suitable for nebulised inhalation, thus its administration to a patient may comprise inhalation of the formulation using a nebuliser.
- the formulations of the invention comprise deuterated N,N- dimethyltryptamine compounds, for example a,a-dideutero-N,N-dimethyltryptamine (d 2 - DMT), a,a,p,p-tetradeutero-N,N-dimethyltryptamine (d4-DMT), N,N- di(trideuteromethyl)tryptamine (d 6 -DMT), a,a-dideutero-N,N- di(trideuteromethyl)tryptamine (d 8 -DMT), and a,a,p,
- a lower dose may be effective, rendering the formulation of the invention particularly suitable for lower dose volumes.
- the invention provides a lyophilised powder formulation comprising a formulation as defined in the first aspect of the invention which has been lyophilised (i.e. freeze dried).
- Lyophilisation also known as freeze drying or cryodesiccation
- Lyophilisation is a drying process carried out at low temperature. Lyophilisation generally involves reducing temperature and pressure to below the substance's triple point and removing the frozen solvent (e.g. water ice) by sublimation.
- lyophilisation may be carried out at temperatures of from about -50 °C to -80 °C, preferably about -70 °C, and pressures of from about 1000 Pa (0.01 bar) to about 100 Pa (0.001 bar), preferably about 800 Pa (0.008 bar).
- the invention provides a method of preparing a lyophilised powder formulation as defined in the tenth aspect, comprising drying the formulation as defined in the first aspect of the invention by lyophilisation.
- the invention provides a method of preparing an aqueous formulation comprising mixing the lyophilised powder formulation as defined in the tenth aspect or as prepared in the method of the eleventh aspect into water to provide a formulation comprising the salt of an optionally substituted dimethyltryptamine compound, the buffer which is separate to the salt, the base agent and water to provide a formulation having a pH of from about 5 to about 6.5, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg.
- the formulation may have a pH of from about 5 to about 6, or a pH of from 5 to 6.
- Synthesis of the compounds for use in the formulations of the invention may be carried out according to the schemes and examples described in WO 2020/245133 A1 , WO 2021/116503 and WO 2021/089873 A1 (all Small Pharma Ltd).
- the extent of deuteration was determined according to the method described in WO 2020/245133 A1 , WO 2021/116503 and WO 2021/089873 A1 .
- N.N-DMT 220.9 g (as free base) was prepared as N.N-DMT fumarate, using the chemistry disclosed in Scheme 2 and the Examples section of WO 2021/089873. An additional 4-6 g of six partially deuterated mixtures were also produced using modified conditions.
- the deuterated dimethyltryptamine compounds include a-protio,a-deutero-dimethyltryptamine and a,a- dideutero-dimethyltryptamine.
- 5- and 4-Substituted dimethyltryptamine and deuterated dimethyltryptamine compounds may be prepared by analogous processes, using the appropriate starting materials.
- 3-indoleacetic acid may be replaced with 5-methoxyindole-3-acetic acid (see synthesis of a,a-dideutero-5-methoxydimethyltryptamine described below) or
- 5-methoxyindole-3-acetic acid for example from Sigma-Aldrich (code M14935-1G), for 4-methoxyindole-3-acetic acid see for example Aaron chemicals (code AR00VTP1)).
- Stage 1 (coupling of 3-indoleacetic acid and cfe-dimethylamine), was carried out according to the process described for Example 4, Stage 1 above Stage 2
- LiAID 4 (1 M in THF, 17.3 ml_, 17.28 mmol) was added to a suspension of the product of Stage 1 (4.0 g, 19.20 mmol) in THF (10 mL) at ⁇ 30 °C. The resulting reaction was heated to 60-65 °C and stirred for 2 hours. HPLC analysis indicated complete consumption of the stage 1 with 97.3% product formed. The reaction was cooled to room temperature and quenched into aqueous Rochelle’s salts (10 g in 30 mL water) at ⁇ 30°C. After stirring for 1 hour, the phases were separated. The aqueous phase was extracted with THF (20 mL).
- Example 6 The product of Example 6, Stage 1 was reacted with LiAIH 4 in THF according to the process described for Stage 2 of Example 4. The reaction was carried out on a 9 g scale to produce cfe-5-MeO-DMT as an amber oil with a yield of 8.22g (7.40g active, 87.3%) and 98.4% purity by HPLC. Molecular weight: 224.34
- the fumarate salt of cfe-5-MeO-DMT was produced according to the process described for Stage 3 of Example 4. 6.04g (65%) of an off-white solid was obtained with a purity of 99.61 % by HPLC. NMR and XRPD data indicated the hemi-salt was isolated. Molecular weight: 564.74 (as hemi-salt)
- the fumarate salt of cfa-5-MeO-DMT was produced according to the process described for Stage 3 of Example 4. 9.6 g of the product cfa-5-MeO-DMT fumaric acid was obtained with 99.71% purity by HPLC. Molecular weight: 342.42. Extent of deuteration.
- D6-5-hydroxydimethyltryptamine and ds-S-hydroxydimethyltryptamine may be prepared by a process analogous to that described for Examples 6 and 7 respectively, using 5-hydroxy-3-indoleacetic acid as a starting material.
- d 6 -5- hydroxydimethyltryptamine and ds-S-hydroxydimethyltryptamine may be prepared from d 6 -5-methoxydimethyltryptamine and d 8 -5-methoxydimethyltryptamine, respectively, by demethylation of the 5-methoxy group using standard procedures, e.g. BBr 3 demethylation.
- EXAMPLE 8 An in vivo investigation pharmacokinetic (PK) profile
- PK pharmacokinetic
- a cassette dose of 3.5 mg/kg SPL026 fumarate and 3.5 mg/kg SPL028viii fumarate were administered as a single IM dose in 4 different male animals, to allow for a direct interanimal comparison of SPL026 and SPL028viii and thereby, avoid confounding effects of inter-animal variability.
- 3.5 mg/kg and 10mg/kg SPL028i fumarate were administered as a single IM dose in 4 different male animals.
- IM dosing apparatus consisted of an appropriately sized insulin syringe. Injection site were shaved the morning of dosing. During dosing, the dose was dispensed directly into the thigh muscle.
- serial whole blood samples (ca. 200pL) will be collected into individual K 2 EDTA treated containers from a lateral tail vein via an indwelling cannula. Samples were collected at the following times post dose:
- Concentrations of DMT and d 8 -DMT were quantified with a target Lower limit of Quantification (LLOQ) of ca 0.310 ng/mL of DMT, ds-DMT and d2-DMT using 20.0 pL of rat plasma and were qualified using the following methods:
- Sensitivity - Minimum signal to noise at LLOQ concentration must be 5:1.
- Stability - Stability in matrix for QC Med in replicate will be assessed for at least 2 hours at the sample processing temperature for DMT only. Acceptance criteria - precision (CV) and accuracy (RE) ⁇ 20%.
- Figure 1A and 1B show linear and semi-log plots of the mean DMT (SPL026), d 8 -DMT (SPL028viii) and d 2 -DMT (SPL028i) concentration overtime following 3.5mg/kg fumarate IM dose (added as a cassette), in vivo.
- Figure 1A Linear plot
- Figure 1 B Semi-log plot
- SEM error bars SEM error bars.
- Figure 2A and 2B shows linear and semi-log plots of the mean d 2 -DMT (SPL028i) concentration over time following 3.5mg/kg and lOmg/kg fumarate IM doses in vivo.
- Figure 2A Linear plot
- Figure 2B Semi-log plot, SEM error bars.
- Dose response relationship level differences in Cmax and AUCo-inf were significantly different from each other (p ⁇ 0.05* and p ⁇ 0.001***, respectively) indicating a significant dose-response relationship.
- a Britton- Robinson (B-R) buffer system (also known as a universal buffer) was used to vary the pH.
- a B-R buffer system typically consists of a mixture of 0.04 M boric acid, 0.04 M phosphoric acid and 0.04 M acetic acid and is titrated to the desired pH with 0.2 M sodium hydroxide. The system enables the pH to be varied while holding the osmolality constant.
- each formulation was measured at preparation, following 7 days storage at 40°C and then further storage over an additional 3 days at 40°C and 7 days at 50°C (so a total further storage of 10 days). Analysis of these formulations was performed on preparation, and then after 7 and 17 days storage for content (assay) and related substances.
- the concentration of DMT fumarate was determined by HPLC at preparation and on the two subsequent stability occasions (Table 2). All results confirmed accurate preparation with no significant concentration changes on either Day 7 or Day 17. The only significant change over the course of the experiment was a drop in concentration following light stressing of the aliquot of the nominal pH 7 formulation. This was accompanied by a significant increase in observed degradants.
- Table 1 shows that pH stability decreased with increasing pH, in particular for formulations with pH > 7.
- Table 3 clearly shows that the amount of related substances increased with increasing pH, indicating decreased stability.
- Example Formulation (25 mq/ml , pH 5.5)
- Example formulations comprising a co-solvent, surfactant, buffer, pH adjuster or tonicity agent, or other excipient.
- compositions of the invention may comprise one or more of the excipients listed above.
- DS refers to the optionally substituted dimethyltryptamine compound for use in the formulations of the present invention.
- Example 9 N,N-Dimethyltryptamine pH-solubility pH solubility samples were prepared in 0.5M Britton Robinson (BR) buffer. Prior to adding N,N-dimethyltryptamine, a quantity of NaOH was added to the BR buffer as required to ensure the required pH. The total volume of BR buffer plus required amount of NaOH was 5 ml for each pH tested (pH 4, 5, 6, 7, 8, 9 & 10). 150 mg of N,N- dimethyltryptamine was then added and the pH checked before shaking overnight at ambient temperature. The solubility of N,N-Dimethyltryptamine was determined at varying pH at 25 °C as shown in the following table and in Figure 3:
- Solubility of 90 mg/mL or greater was observed at a pH between about 4 and about 6, with the highest solubility observed at a pH of around 5.
- a solubility headspace of around 2-3 fold is ideally allowed to reduce the risk of precipitation on long term storage and/or temporary storage at temperatures below the recommended storage temperature.
- These data support a 100mg/2.5ml_ (40mg/ml) dose at a pH of from about 5 to about 6.5, while achieving the desirable 2-3 fold solubility headspace at 25 °C.
- Example 10 Example Formulations Example formulations of the invention are as set out in the following table. q.s. means a sufficient quantity
- Example 11 Stability Formulations of DMT fumarate (Example 2), and of deuterated DMT fumarate (Example 2), prepared in accordance with Example 10, were assessed for stability after storage for 3 months at 2-8°C, at 25°C/60% RH and at 40°C/75% RH.
- a pharmaceutical formulation suitable for intramuscular injection and/or nebuliser inhalation comprising a salt of an optionally substituted dimethyltryptamine compound; and water; wherein the formulation has a pH of from about 5 to about 6, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg.
- a pharmaceutical formulation suitable for intramuscular injection and/or nebuliser inhalation comprising a salt of an optionally substituted dimethyltryptamine compound; and water; wherein the formulation has a pH of from about 5 to about 6.5, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg.
- a pharmaceutical formulation suitable for intramuscular injection and/or nebuliser inhalation comprising a salt of an optionally substituted dimethyltryptamine compound; a base agent, water, and optionally a buffer which is separate to the salt; wherein the formulation has a pH of from about 5 to about 6, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg; and wherein the formulation comprises a dose of the optionally substituted dimethyltryptamine compound within a volume for injection or inhalation of 5 ml or less.
- a pharmaceutical formulation suitable for intramuscular injection and/or nebuliser inhalation comprising a salt of an optionally substituted dimethyltryptamine compound; a base agent, water, and optionally a buffer which is separate to the salt; wherein the formulation has a pH of from about 5 to about 6.5, a concentration of about 10 mg/ml as freebase or greater, and an osmolality of from about 250 to about 350 mOsm/Kg; and wherein the formulation comprises a dose of the optionally substituted dimethyltryptamine compound within a volume for injection or inhalation of 5 ml or less.
- formulation comprises an effective dose of an optionally substituted dimethyltryptamine compound for use in psychedelic assisted therapy within a volume of 5 ml or less.
- the salt of the optionally substituted dimethyltryptamine compound comprises a Bransted acid having a pKa of from about 3 to about 5 and a compound of Formula I: Formula I wherein:
- R 1 is independently selected from -R 4 , -OH, -OR 4 , -O(CO)R 4 , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2 is C( X H) 3 ;
- R 3 is C( X H) 3 ; each R 4 is independently selected from Ci-C 4 alkyl; and each X H and y H is independently selected from protium or deuterium.
- the salt of the optionally substituted dimethyltryptamine compound comprises a Bransted acid having a pKa of from about 3 to about 5 and a compound of Formula IA or of Formula IB:
- R 1a is independently selected from -R 4a , -OH, -OR 4a , -O(CO)R 4a , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2a is C( xa H) 3 ;
- R 3a is C( xa H) 3 ; each R 4a is independently selected from Ci-C 4 alkyl; and each xa H and ya H is independently selected from protium or deuterium;
- R 1b is independently selected from -R 4b , -OH, -OR 4b , -O(CO)R 4b , monohydrogen phosphate, -F, -Cl, -Br and -I; n is selected from 0, 1 , 2, 3 or 4;
- R 2b is C( xb H) 3 ;
- R 3b is C( xb H) 3 ; each R 4b is independently selected from Ci-C 4 alkyl; and each xb H, yb H and Z H is independently selected from protium or deuterium.
- the salt of the optionally substituted dimethyltryptamine compound comprises (i) a compound of Formula I, wherein n is 0; or n is 1 and R 1 is in the 4- or 5-position; or (ii) a compound of Formula IA, wherein n is 0; or n is 1 and R 1a is in the 4- or 5-position, or (iii) a compound of Formula IB, wherein n is 0; or n is 1 and R 1b is in the 4- or 5-position 2.
- the salt of the optionally substituted dimethyltryptamine compound comprises (i) a compound of Formula I, wherein each R 1 is independently selected from -OH, -OMe, -OCD 3 , -OAc, - O(CO)Me, and monohydrogen phosphate; or (ii) a compound of Formula IA, wherein each R 1a is independently selected from -OH, -OMe, -OCD 3 , -OAc, - O(CO)Me, and monohydrogen phosphate, or (iii) a compound of Formula IB, wherein each R 1b is independently selected from -OH, -OMe, -OCD 3 , -OAc, - O(CO)Me, and monohydrogen phosphate.
- the salt of the optionally substituted dimethyltryptamine compound comprises (i) a compound of Formula I, wherein R 2 is CH 3 and R 3 is CH 3 ; or (ii) a compound of Formula IA, wherein R 2a is CH 3 and R 3a is CH 3 , or (iii) a compound of Formula IB, wherein R 2b is CH 3 and R 3b is CH 3 .
- the salt of the optionally substituted dimethyltryptamine compound comprises (i) a compound of Formula I, wherein R 2 is CH 3 and R 3 is CD 3 ; or (ii) a compound of Formula IA, wherein R 2a is CH 3 and R 3a is CD 3 , or (iii) a compound of Formula IB, wherein R 2b is CH 3 and R 3b is CD 3 .
- the salt of the optionally substituted dimethyltryptamine compound comprises (i) a compound of Formula I, wherein one y H is H and one y H is D; or (ii) a compound of Formula IA, wherein one ya H is H and one ya H is D; or (iii) a compound of Formula IB, wherein one yb H is H and one yb H is D.
- any one of clauses 10 to 19, wherein the salt of the optionally substituted dimethyltryptamine compound comprises a compound of Formula IB, wherein one Z H is H and one Z H is D.
- the formulation of any one of clauses 9 to 22 wherein n is 1 and R 1 or R 1a or R 1b is 4-acetoxy.
- the formulation of any one of clauses 9 to 22 wherein n is 1 and R 1 or R 1a or R 1b is 5-methoxy or trideutero-5-methoxy.
- the formulation of any one of clauses 1 to 9, wherein the optionally substituted dimethyltryptamine compound is N,N-dimethyltryptamine.
- the optionally substituted dimethyltryptamine compound is selected from a,a-dideutero-N,N- dimethyltryptamine (d 2 -DMT) a,a,p,p-tetradeutero-N,N-dimethyltryptamine (d 4 - DMT), N,N-di(trideuteromethyl)tryptamine (de-DMT), a,a-dideutero-N,N- di(trideuteromethyl)tryptamine (d 8 -DMT), a,a,p,
- the formulation further comprises a buffer which is separate to the salt.
- the buffer comprises an acetate salt and acetic acid; or a citrate salt and citric acid; or a phosphate salt and phosphoric acid; or the buffer comprises an acetate salt, a citrate salt, or a phosphate salt.
- the formulation consists essentially of the salt of the optionally substituted dimethyltryptamine compound, water, and the base agent, and optionally one or more agents selected from a tonicity agent, a buffer, a co-solvent, a preservative, and an antioxidant.
- kit suitable for preparing a formulation of any one of clauses 3 to 57 comprising a salt of an optionally substituted dimethyltryptamine compound; optionally a tonicity agent; a base agent and optionally a buffer which is separate to the salt.
- a method of preparing a pharmaceutical formulation as defined in any one of clauses 1 to 57 comprising contacting the salt of the optionally substituted dimethyltryptamine compound, water and optionally a buffer, and optionally a tonicity agent.
- clause 64 or clause 65 which further comprises adjusting the pH with a pH adjuster, which is preferably hydrochloric acid.
- the method of any one of clauses 60 to 66 further comprising sparging the formulation with an inert gas.
- the psychiatric or neurological disorder is selected from the group consisting of (i) an obsessive compulsive disorder, (ii) a depressive disorder, (iii) an anxiety disorder, (iv) substance abuse and gambling disorders, and (v) an avolition disorder.
- a method of treating a psychiatric or neurological disorder comprising administering to a patient in need thereof a formulation as defined in any one of clauses 1 to 57.
- the method of clause 71 wherein the psychiatric or neurological disorder is as defined in clause 70.
- the method of clause 71 wherein the formulation as defined in any one of clauses 1 to 57 is administered in combination with psychotherapy.
- the formulation comprises: a) the salt of an optionally substituted dimethyltryptamine compound selected from a,a-dideutero-N,N-dimethyltryptamine (d 2 -DMT) a,a,p,
- the formulation has a pH of from about 5 to about 6.5, or a pH of from about 5 to about 6, a concentration of from about 15 mg/mL to about 70 mg/mL (as the freebase equivalent), and an osmolality of from about 250 to about 350 mOsm/Kg; and wherein the formulation comprises a dose of the optionally substituted dimethyltryptamine compound in the range of from about 10 mg to about 100 mg within a volume of 5 ml or less.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3238583A CA3238583A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
AU2022393234A AU2022393234A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110143066A TW202237565A (en) | 2020-12-01 | 2021-11-18 | Deuterated compounds |
EPPCT/EP2021/082227 | 2021-11-18 | ||
TW110143066 | 2021-11-18 | ||
PCT/EP2021/082227 WO2022117359A1 (en) | 2020-12-01 | 2021-11-18 | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
GBGB2119021.0A GB202119021D0 (en) | 2021-11-18 | 2021-12-24 | Injectable and inhalable formulations |
GB2119021.0 | 2021-12-24 | ||
US202217574424A | 2022-01-12 | 2022-01-12 | |
US17/574,424 | 2022-01-12 | ||
EPPCT/EP2022/055324 | 2022-03-02 | ||
EP2022055324 | 2022-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023089132A1 true WO2023089132A1 (en) | 2023-05-25 |
Family
ID=84440034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/082486 WO2023089132A1 (en) | 2021-11-18 | 2022-11-18 | Injectable and inhalable formulations |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2022393234A1 (en) |
CA (1) | CA3238583A1 (en) |
WO (1) | WO2023089132A1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008049116A2 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
WO2020169850A1 (en) * | 2019-02-22 | 2020-08-27 | Gh Research Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
WO2020245133A1 (en) | 2019-06-03 | 2020-12-10 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
WO2021089873A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Method of synthesis |
WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
WO2022043227A1 (en) * | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
WO2022117359A1 (en) * | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
-
2022
- 2022-11-18 WO PCT/EP2022/082486 patent/WO2023089132A1/en active Application Filing
- 2022-11-18 CA CA3238583A patent/CA3238583A1/en active Pending
- 2022-11-18 AU AU2022393234A patent/AU2022393234A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008049116A2 (en) * | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
WO2020169850A1 (en) * | 2019-02-22 | 2020-08-27 | Gh Research Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating depression |
WO2020245133A1 (en) | 2019-06-03 | 2020-12-10 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
WO2021089873A1 (en) | 2019-11-07 | 2021-05-14 | Small Pharma Ltd | Method of synthesis |
WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
WO2022043227A1 (en) * | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
WO2022117359A1 (en) * | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Non-Patent Citations (15)
Title |
---|
A. D. JENKINS ET AL., PURE & APPL. CHEM, vol. 68, 1996, pages 2287 - 2311 |
BARKER STEVEN A. ET AL: "N, N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function", FRONTIERS IN NEUROSCIENCE, vol. 12, 1 January 2018 (2018-01-01), pages 536 - 10, XP055871209, Retrieved from the Internet <URL:https://mberstecher.de/fnins-12-00536.pdf> DOI: 10.3389/fnins.2018.00536 * |
C. TIMMERMANN ET AL., SCI. REP, vol. 9, 2019, pages 16324 |
CARHART-HARRISGOODWIN, NEUROPSYCHOPHARMACOLOGY, vol. 42, 2017, pages 2105 - 2113 |
D. K. FARIA ET AL., M. E. MENDES, N. M. SUMITA, PATOL. MED. LAB., vol. 53, no. 1, 2017, pages 38 - 45 |
GRIFFITHS ET AL., JOURNAL OF PSYCHOPHARMACOLOGY, vol. 30, no. 12, 2016, pages 1181 - 1197 |
L. HOOPER ET AL., BMJ OPEN, vol. 5, no. 10, 2015, pages e008846 |
M. F. POWELLT. NGUYENL. BALOIAN, PDA J. PHARM. SCI. TECHNOL, vol. 52, 1998, pages 238 - 311 |
P. H. STAHLC. G. WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2002, WEINHEIM/ZURICH:WILEY-VCHA/HCA |
P. J. SHESKEYW G COOKC G CABLE: "Handbook of Pharmaceutical Excipients", 2017, PHARMACEUTICAL PRESS |
PIRIES ET AL., PHYTOCHEM. ANAL., vol. 20, 2009, pages 149 - 153 |
S. A. BARKER, FRONT. NEUROSCI, vol. 12, no. 536, 2018, pages 1 - 17 |
SILVIERA ET AL., MOLECULES, vol. 25, 2020, pages 2072 |
STRASSMAN RICK J ET AL: "Dose-Response Study of N,N-Dimethyltryptamine in Humans: II. Subjective Effects and Preliminary Results of a New Rating Scale", ARCHIVES OF GENERAL PSYCHIATRY, vol. 51, no. 2, 1 January 1994 (1994-01-01), pages 98 - 108, XP055871027 * |
USACH ET AL., ADV. THEN, vol. 36, 2019, pages 2986 - 2996 |
Also Published As
Publication number | Publication date |
---|---|
AU2022393234A1 (en) | 2024-06-06 |
CA3238583A1 (en) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11406619B2 (en) | Injectable formulations | |
KR102636385B1 (en) | Injectable preparation | |
US20220062237A1 (en) | Injectable formulation | |
WO2021244831A1 (en) | Therapeutic solid dosage forms | |
EP4031529B1 (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
EA002174B1 (en) | Pharmaceutical compositions containing eletriptan hemisulphate and caffeine | |
US20220081396A1 (en) | Deuterated compounds | |
US20230181530A1 (en) | Deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
Layzell et al. | Injectable formulation | |
WO2022195011A1 (en) | Psilocybin analogs, salts, compositions, and methods of use | |
AU2022393234A1 (en) | Injectable and inhalable formulations | |
US20230149293A1 (en) | Injectable and inhalable formulations | |
NZ562158A (en) | Stannsoporfin compositions and administration | |
WO2022117640A1 (en) | Inhalable formulations | |
BR112022022198B1 (en) | INJECTABLE FORMULATION | |
US20220169606A1 (en) | Compositions and compounds for bioanalysis | |
US20240016782A1 (en) | Inhalable formulations | |
US20220168274A1 (en) | Parenteral Formulation | |
CN116761599A (en) | Deuterated or partially deuterated N, N-dimethyltryptamine compounds | |
WO2023156559A1 (en) | Bilastine composition for once-daily parenteral administration | |
EP4149460A1 (en) | Therapeutic solid dosage forms | |
EP4308548A1 (en) | Psilocybin analogs, salts, compositions, and methods of use | |
JP2016056105A (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22818741 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3238583 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401003192 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022393234 Country of ref document: AU Ref document number: AU2022393234 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024009571 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022393234 Country of ref document: AU Date of ref document: 20221118 Kind code of ref document: A |